Related Experiment Video

Updated: Apr 30, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.8K

[Tofacitinib]

S Döker1, M Dewenter1, A El-Armouche1

  • 1Institut für Pharmakologie, Universitätsmedizin Göttingen.

Deutsche Medizinische Wochenschrift (1946)
|May 1, 2014
PubMed

Insights

Tofacitinib is the first Janus kinase inhibitor approved for rheumatoid arthritis therapy. This article reviews its efficacy and safety, discussing its potential for EU approval.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Context:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease.
  • Janus kinase (JAK) inhibitors represent a novel therapeutic class for RA.
  • Tofacitinib is the first approved JAK inhibitor in the USA for RA.

Purpose:

  • To discuss the therapeutic potential of Tofacitinib.
  • To review current efficacy and safety data of Tofacitinib therapy.
  • To consider the prospective approval of Tofacitinib in the European Union.

Summary:

  • Tofacitinib, a Janus kinase inhibitor, has demonstrated efficacy in Phase III trials for rheumatoid arthritis, both as monotherapy and in combination treatments.
  • The article evaluates the pharmacological approach of Tofacitinib, presenting current data on its effectiveness and safety profile.
  • Special attention is given to the potential regulatory approval of Tofacitinib within the European Union.

Impact:

  • Provides a comprehensive overview of Tofacitinib for clinicians and researchers.
  • Informs about the efficacy and safety of a new class of drugs for rheumatoid arthritis.
  • Highlights the potential expansion of Tofacitinib's therapeutic availability in the EU.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

9.7K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.2K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K